In summary, our study suggests that pharmacological inhibition of HO-1 can efficiently improve the effect of targeted therapy against BRAFV600 mutated melanoma, both by favoring drug-induced cancer cell death and by restoring drug-impaired NK recognition. Here, HMOX1 is linked to melanoma.